<unk>  is used to treat tardive dyskinesia in adults. Tardive dyskinesia is a drug-induced neurological injury characterized by involuntary movements. The clinical trials that led to FDA approval of<unk>  were 6 weeks in duration. An industry-sponsored study has studied the use of<unk>  for up to 48 weeks, in which it was found to be safe and effective for maintaining short-term (6 week) improvements in tardive dyskinesia.
Valbenazine
Brinzolamide
Nitroxazepine
Ranolazine
Brotizolam
Benazepril
Methyldopa
Propranolol